Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid Leukemia (AML...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Celgene
Collaborators
NCT07216443 · Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, and more
NCT06852222 · Leukemia, Myeloid, Acute
NCT06580106 · Leukemia, Myeloid, Acute
NCT06501196 · Leukemia, Leukemia, Myeloid, and more
NCT05305859 · Leukemia, Myeloid, Acute, Relapsed Adult AML, and more
Local Institution - 104
Stanford, California
Local Institution - 110
Denver, Colorado
Local Institution - 105
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions